Late Friday, Miami-based Ivax (nyse: IVX - news - people ) said it had received tentative approval to sell generic versions of diabetes drug Glucophage, despite brandmaker Bristol-Myers Squibb (nyse: BMY - news - people ) trying to holdthingsup with discussions regarding the generic drug's label.